Evidence map›Paper›PMID 40471272›Full record

ReviewJournal of neural transmission (Vienna, Austria : 1996)2025

Vascular parkinsonism: an update.

Kurt A Jellinger

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neural transmission (Vienna, Austria : 1996), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Kurt A JellingerInstitute of Clinical Neurobiology, Alberichgasse 5/13, A-1150, Vienna, Austria. kurt.jellinger@univie.ac.at.ORCID 0000-0002-9641-7649

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular parkinsonism (VP), resulting from cerebrovascular disease, is a rare disorder with a characteristic motor and non-motor clinical profile distinct from sporadic/idiopathic Parkinson disease (PD) and other parkinsonian disorders. It accounts for 3-6% of all parkinsonian syndromes and may overlap with other parkinsonisms. Clinical features of VP are heterogenous and include bilateral rigidity with lower body predominance, bradykinesia, postural instability, shuffling gait, falls, corticospinal symptoms and cognitive impairment, tremor being rare or absent. An international working group recommended three VP subtypes: (1) the acute or subacute poststroke type: asymmetric parkinsonism due to involvement of the nigrostriatal system and response to dopaminergic drugs, (2) the more frequent insidious onset subtype due to ischemic deep white matter lesions and/or lacunar infarcts presents with progressive, symmetrical parkinsonism, prominent postural instability, gait impairment, corticospinal, pseudobulbar, urinary and cognitive symptoms, and poor levodopa response; (3) mixed VP/PD and other neurodegenerative parkinsonisms showing overlaps between these forms, with upper and lower body rigidity, resting tremor, dementia and positive levodopa response. Neuroimaging shows brain atrophy, widespread deep white matter lesions, lacunar infarcts and rare direct damage to nigrostriatal areas. Advanced MRI techniques and dopamine transporter imaging may be useful in the differentiation of VP with PD and other neurodegenerative parkinsonian syndromes. Neuropathology of VP reveals multiple subcortical ischemic lesions due to small vessel disease in basal ganglia and deep white matter, less often lesions of striatum, and substantia nigra involving cortico-basal ganglia-cortical and other neuronal circuits. Lewy pathology is usually absent. New molecular biomarkers will help to differentiate VP from other parkinsonian syndromes. The response of VP to different therapeutic strategies is modest. Further studies are warranted to explore the role of vascular lesions in the pathogenesis of VP and to demonstrate the efficacy of new therapy options.

Indexed as

Cerebrovascular DisordersParkinsonian DisordersHumansCerebrovascular diseaseNeuroimagingTreatment optionsVascular parkinsonismWhite matter lesions

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.